ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®

[Manouche]

«After two and a half years of arbitration proceedings concerning BESREMi® (Ropeginterferon alfa-2b), the decision by the ICC Arbitral Tribunal has now been made. In 2017 PharmaEssentia had attempted to terminate the contractual agreement with AOP Orphan. The arbitral award states that the termination of the aforementioned contract was unjustified and thus that the license agreement remains in full force and effect. Consequently, AOP Orphan is entitled to payment of damages for project delays caused by PharmaEssentia, resulting in delays of the approval of the medicinal product for human use BESREMi® in Europe and delays in supply to patients affected by polycythaemia vera. On these grounds, the ICC has awarded AOP Orphan damages of a total of approximately EUR 143 million.  »

newsfox.com/news/20201028019

[Mazcd Partner MPNVoice]

important to note that drug BESREMI is approved in the EU. MPN voice has no specific additional comment

[Manouche in reply to Mazcd]

Besremi is approved in the EU but has never or rarely been prescribed, so far. Too expensive. The cost of this drug could be partly explained by the legal procedures between AOP Orphan and PharmaEssentia. This could change now.